Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the manufacturer of pomalidomide (POM; Imnovid(®), Celgene) to submit evidence regarding the clinical and cost effectiveness of the drug in combination with dex...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Pharmacoeconomics
Główni autorzy: Büyükkaramikli, Nasuh C., de Groot, Saskia, Fayter, Debra, Wolff, Robert, Armstrong, Nigel, Stirk, Lisa, Worthy, Gill, Albuquerque de Almeida, Fernando, Kleijnen, Jos, Al, Maiwenn J.
Format: Artigo
Język:Inglês
Wydane: Springer International Publishing 2017
Hasła przedmiotowe:
Review Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805808/
https://ncbi.nlm.nih.gov/pubmed/29086363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0581-6
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy